



MEDINCELL SA

2025 CDP Corporate Questionnaire 2025

Word version

Important: this export excludes unanswered questions

This document is an export of your organization's CDP questionnaire response. It contains all data points for questions that are answered or in progress. There may be questions or data points that you have been requested to provide, which are missing from this document because they are currently unanswered. Please note that it is your responsibility to verify that your questionnaire response is complete prior to submission. CDP will not be liable for any failure to do so.

[Read full terms of disclosure](#)

▪

Contents

C14. SME Introduction

(14.1) In which language are you submitting your response?

Select from:

☒ English

(14.2) Select the currency used for all financial information disclosed throughout your response.

Select from:

☒ EUR

(14.3) Provide an overview and introduction to your organization.

(14.3.1) Organization type

Select from:

☒ Publicly traded organization

(14.3.2) Description of organization

Medincell is a clinical and commercial-stage biopharmaceutical licensing company developing long-acting injectable drugs in a wide range of therapeutic areas. Our innovative treatments aim to ensure compliance with medical prescriptions, improve efficacy and accessibility, and reduce their environmental footprint. They combine active ingredients with our proprietary BEPO® technology, which controls the release of a drug at a therapeutic level for several days, weeks or months from the subcutaneous or local injection of a simple, fully bioresorbable deposit measuring just a few millimeters. The first treatment based on BEPO® technology, intended for the treatment of schizophrenia, was approved by the FDA in April 2023, and is now distributed in the United States by Teva under the name UZEDY® (the BEPO® technology is licensed to Teva under the name SteadyTeq™). We collaborate with leading pharmaceutical companies and foundations to improve global health through new treatment options. He

[Fixed row]

(14.4) State the end date of the year for which you are reporting data.

	End date of reporting year	Alignment of this reporting period with your financial reporting period
	03/30/2025	Select from: <input checked="" type="checkbox"/> Yes

[Fixed row]

(14.5) How do the entities you are including in your CDP response compare to those included in your financial statements?

	Are the entities included in your CDP response the same as those included used in your financial statements?
	Select from: <input checked="" type="checkbox"/> Yes, the entities included in my CDP disclosure are the same as those included in my financial statements

[Fixed row]

(14.6) Does your organization have an ISIN code or another unique identifier (e.g., Ticker, CUSIP, etc.)?

ISIN code – bond

(14.6.1) Does your organization use this unique identifier?

Select from:

☒ No

ISIN code – equity

(14.6.1) Does your organization use this unique identifier?

Select from:

☒ Yes

(14.6.2) Provide your unique identifier

FR0004065605

CUSIP number

(14.6.1) Does your organization use this unique identifier?

Select from:

☒ No

Ticker symbol

(14.6.1) Does your organization use this unique identifier?

Select from:

☒ Yes

(14.6.2) Provide your unique identifier

MEDCL

SEDOL code

(14.6.1) Does your organization use this unique identifier?

Select from:

☒ No

LEI number

(14.6.1) Does your organization use this unique identifier?

Select from:

☒ Yes

(14.6.2) Provide your unique identifier

969500R79U6PXCL2FF46

D-U-N-S number

(14.6.1) Does your organization use this unique identifier?

Select from:

☒ Yes

(14.6.2) Provide your unique identifier

266373112

Other unique identifier

(14.6.1) Does your organization use this unique identifier?

Select from:

☒ No

[Add row]

(14.7) Select the countries/areas in which the entities reported in 14.5 are based and/or conduct business.

Select all that apply

☒ France

C15. SME Identification, Assessment and Management of Risks and Opportunities

(15.1) Does your organization have a process for identifying, assessing, and managing environmental risks and opportunities?

(15.1.1) Process in place

Select from:

☒ Yes

(15.1.2) Risks and/or opportunities evaluated in this process

Select from:

☒ Both risks and opportunities

(15.1.3) Frequency of assessment

Select from:

☒ Annually

(15.1.4) Please explain the process

*The risks associated with taking sustainability objectives into account for a technology-based pharmaceutical company at the clinical stage are intrinsically linked to those of the pharmaceutical industry. The risks involved in addressing sustainability objectives for a clinical-stage pharmaceutical technology company are intrinsically linked to those of the pharmaceutical industry. Taking into account the growing expectations of stakeholders becomes fundamental. We have therefore considered twelve sustainability issues specific to MedinCell, as well as the related risks considered to be significant, in light of stakeholder requirements and the Company's purpose. Within those 12 CSR high level risks, 3 high level risks were Environmental and Climate-related (detailed below). Risk 1: Risks related to a lack of environmental management by MedinCell or certain stakeholders and in certain regions. Risks of worsening of phenomena linked to climate change (Rated: probability of occurrence**/estimated impact */degree of net criticality **) Risk 2: Resources management Risks associated with the water-intensive pharmaceutical industry. Risks of poor environmental management of raw material resources linked to BEPO technology. Risks of environmental degradation in certain regions linked to the supply chain (Rated: probability of occurrence*/estimated impact **/degree of net criticality**) Risk 3: Pollution & biodiversity Risks associated with the possibility that, for certain products, the technology may not reduce the impact of pharmaceutical compounds, or may be more environmentally impactful overall than oral treatment. Risk of environmental degradation. Operational environmental risks and opportunity are assessed through a risk FMEA analysis considering any impact on water, air, soil and biodiversity from MedinCell direct activities and thus link to its core business activities. The outcome is a mitigation plan on the high and medium*

*residual risks. The significance of the risks was assessed on the basis of: - The probability of occurrence (Low: *; Medium: ** and High: ***), weighted taking into account current societal expectations, MedinCell's dependence on its commercial partners and also its scope of action. - The estimated impact (Low: *; Medium: ** and High: ***), taking into account the reputational, litigation and financial impacts and also the achievement of the Company's purpose (raison d'être). - The degree of net criticality determined (probability of occurrence x potential impact) after taking into account the current stage of development of the Company's activities and its CSR policy aimed at managing these risks.*

[Fixed row]

C16. SME Disclosure of Risks and Opportunities

(16.1) Are you aware of any risks created by environmental issues which have had a substantive effect on your organization in the reporting year or may in the future?

	Environmental risks identified
Climate change	Select from: <input checked="" type="checkbox"/> Yes, both in direct operations (our own operations) and upstream/downstream value chain (our suppliers, distributors, and customers)

[Fixed row]

(16.1.1) Provide details of the risks created by environmental issues which have had a substantive effect on your organization in the reporting year or may in the future.

Climate change

(16.1.1.1) Risk identifier

Select from:

☒ Risk1

(16.1.1.3) Risk type and primary source of the environmental risk

Acute physical (short term, specific events that change the state of nature)

☒ Heat wave

(16.1.1.4) Value chain stage where the risk occurs

Select from:

☒ Direct operations (our own operations)

(16.1.1.5) Country/area where the risk occurs

Select all that apply

☒ France

(16.1.1.7) Organization-specific description of risk

Increased costs and disruption of temperature-controlled activities as a result of heat waves and rising temperatures, combined with a shortage of energy resources.

(16.1.1.8) Primary financial effect of the risk

Select from:

☒ Increased indirect [operating] costs

(16.1.1.9) Time horizon over which the risk is anticipated to have a substantive effect on the organization

Select all that apply

☒ Medium-term

(16.1.1.10) Likelihood of the risk having an effect within the anticipated time horizons

Select from:

☒ Likely (66–100%)

(16.1.1.11) Magnitude

Select from:

☒ Medium-low

(16.1.1.12) Are you able to quantify the financial effect of the risk?

Select from:

☒ No

(16.1.1.16) Primary response to risk

Compliance, monitoring and targets

☒ Improve monitoring of direct operations

Climate change

(16.1.1.1) Risk identifier

Select from:

☒ Risk3

(16.1.1.3) Risk type and primary source of the environmental risk

Chronic physical (gradual changes to the state of nature)

☒ Increased severity of extreme weather events

(16.1.1.4) Value chain stage where the risk occurs

Select from:

☒ Direct operations (our own operations)

(16.1.1.5) Country/area where the risk occurs

Select all that apply

☒ France

(16.1.1.7) Organization-specific description of risk

By the end of the century, the South of Europe area could be experiencing higher average temperatures more heatwave days, less precipitation in general but more episodes of heavy precipitation and more days of drought. The increase in the frequency of events which are considered as natural disasters could increase insurance costs.

(16.1.1.8) Primary financial effect of the risk

Select from:

- ☒ Increased insurance premiums

(16.1.1.9) Time horizon over which the risk is anticipated to have a substantive effect on the organization

Select all that apply

- ☒ Medium-term
- ☒ Long-term

(16.1.1.10) Likelihood of the risk having an effect within the anticipated time horizons

Select from:

- ☒ More likely than not (50–100%)

(16.1.1.11) Magnitude

Select from:

- ☒ Low

(16.1.1.12) Are you able to quantify the financial effect of the risk?

Select from:

- ☒ No

(16.1.1.16) Primary response to risk

Infrastructure, technology and spending

- ☒ Increase geographic diversity of facilities

Climate change

(16.1.1.1) Risk identifier

Select from:

☒ Risk4

(16.1.1.3) Risk type and primary source of the environmental risk

Chronic physical (gradual changes to the state of nature)

☒ Change in land-use

(16.1.1.4) Value chain stage where the risk occurs

Select from:

☒ Upstream value chain (suppliers)

(16.1.1.5) Country/area where the risk occurs

Select all that apply

☒ Brazil

☒ China

☒ Thailand

(16.1.1.7) Organization-specific description of risk

Disruptions in the bio-based polymer production chain due to climate-related changes in agricultural practices and land use notably in South Asia and Bresil where our ploymer partner has its current raw material supplier.

(16.1.1.8) Primary financial effect of the risk

Select from:

☒ Increased production costs

(16.1.1.9) Time horizon over which the risk is anticipated to have a substantive effect on the organization

Select all that apply

☒ Long-term

(16.1.1.10) Likelihood of the risk having an effect within the anticipated time horizons

Select from:

☒ More likely than not (50–100%)

(16.1.1.11) Magnitude

Select from:

☒ Medium-low

(16.1.1.12) Are you able to quantify the financial effect of the risk?

Select from:

☒ No

(16.1.1.16) Primary response to risk

Diversification

☒ Increase supplier diversification

Climate change

(16.1.1.1) Risk identifier

Select from:

☒ Risk5

(16.1.1.3) Risk type and primary source of the environmental risk

Market

- ☒ Increased cost of raw materials

(16.1.1.4) Value chain stage where the risk occurs

Select from:

- ☒ Upstream value chain (suppliers)

(16.1.1.5) Country/area where the risk occurs

Select all that apply

- ☒ China
- ☒ India
- ☒ Brazil
- ☒ Germany
- ☒ Thailand
- ☒ United States of America

(16.1.1.7) Organization-specific description of risk

An increase in travel and production costs or even the unavailability of certain items due to the scarcity of certain raw materials. Climate change may impact crop yields, leading to a higher cost of bioplastics or animal food. The technology may become more expensive to produce and can impact the product's price (that may affect their accessibility).

(16.1.1.8) Primary financial effect of the risk

Select from:

- ☒ Increased production costs

(16.1.1.9) Time horizon over which the risk is anticipated to have a substantive effect on the organization

Select all that apply

- ☒ Long-term

(16.1.1.10) Likelihood of the risk having an effect within the anticipated time horizons

Select from:

☒ Likely (66–100%)

(16.1.1.11) Magnitude

Select from:

☒ Low

(16.1.1.12) Are you able to quantify the financial effect of the risk?

Select from:

☒ No

(16.1.1.16) Primary response to risk

Policies and plans

☒ Increased use of sustainably sourced materials

Climate change

(16.1.1.1) Risk identifier

Select from:

☒ Risk6

(16.1.1.3) Risk type and primary source of the environmental risk

Policy

☒ Changes to international law and bilateral agreements

(16.1.1.4) Value chain stage where the risk occurs

Select from:

☒ Direct operations (our own operations)

(16.1.1.5) Country/area where the risk occurs

Select all that apply

☒ France

(16.1.1.7) Organization-specific description of risk

Incentive or mandatory policies and regulations, which are progressively introduced to ensure the transition to low-carbon economies and practices and to ensure climate resilience, which could lead to new restrictions and changes to MedinCell's business activities and its value chain (such as carbon pricing, reporting requirements or product regulations) which could in turn generate additional compliance and supply chain adaptation costs

(16.1.1.8) Primary financial effect of the risk

Select from:

☒ Increased compliance costs

(16.1.1.9) Time horizon over which the risk is anticipated to have a substantive effect on the organization

Select all that apply

☒ Medium-term

(16.1.1.10) Likelihood of the risk having an effect within the anticipated time horizons

Select from:

☒ Likely (66–100%)

(16.1.1.11) Magnitude

Select from:

☒ Medium-low

(16.1.1.12) Are you able to quantify the financial effect of the risk?

Select from:

☒ No

(16.1.1.16) Primary response to risk

Compliance, monitoring and targets

☒ Greater due diligence

Climate change

(16.1.1.1) Risk identifier

Select from:

☒ Risk7

(16.1.1.3) Risk type and primary source of the environmental risk

Market

☒ Uncertainty in market signals

(16.1.1.4) Value chain stage where the risk occurs

Select from:

☒ Direct operations (our own operations)

(16.1.1.5) Country/area where the risk occurs

Select all that apply

☒ France

(16.1.1.7) Organization-specific description of risk

The Company may have to rethink its strategy and business activities in order to adapt to climate change, which could lead to additional investments or costs, and change certain aspects of its profitability.

(16.1.1.8) Primary financial effect of the risk

Select from:

☒ Increased capital expenditures

(16.1.1.9) Time horizon over which the risk is anticipated to have a substantive effect on the organization

Select all that apply

☒ Long-term

(16.1.1.10) Likelihood of the risk having an effect within the anticipated time horizons

Select from:

☒ About as likely as not (33–66%)

(16.1.1.11) Magnitude

Select from:

☒ Medium-low

(16.1.1.12) Are you able to quantify the financial effect of the risk?

Select from:

☒ No

(16.1.1.16) Primary response to risk

Policies and plans

☒ Develop a climate transition plan

Climate change

(16.1.1.1) Risk identifier

Select from:

☒ Risk8

(16.1.1.3) Risk type and primary source of the environmental risk

Technology

☒ Transitioning to lower emissions technology

(16.1.1.4) Value chain stage where the risk occurs

Select from:

☒ Direct operations (our own operations)

(16.1.1.5) Country/area where the risk occurs

Select all that apply

☒ France

(16.1.1.7) Organization-specific description of risk

The need to develop technological improvements or innovations to prepare for the low-carbon transition and chronic climate risks (scarcity of raw materials and rising temperatures) which may require significant financial investments in a very competitive environment.

(16.1.1.8) Primary financial effect of the risk

Select from:

☒ Increased capital expenditures

(16.1.1.9) Time horizon over which the risk is anticipated to have a substantive effect on the organization

Select all that apply

☒ Medium-term

☒ Long-term

(16.1.1.10) Likelihood of the risk having an effect within the anticipated time horizons

Select from:

☒ More likely than not (50–100%)

(16.1.1.11) Magnitude

Select from:

☒ Medium

(16.1.1.12) Are you able to quantify the financial effect of the risk?

Select from:

☒ No

(16.1.1.16) Primary response to risk

Infrastructure, technology and spending

☒ Increase investment in R&D

Climate change

(16.1.1.1) Risk identifier

Select from:

☒ Risk9

(16.1.1.3) Risk type and primary source of the environmental risk

Policy

☒ Carbon pricing mechanisms

(16.1.1.4) Value chain stage where the risk occurs

Select from:

- ☒ Direct operations (our own operations)

(16.1.1.5) Country/area where the risk occurs

Select all that apply

- ☒ France

(16.1.1.7) Organization-specific description of risk

During the transition to low-carbon economies and practices, punitive measures based on the polluter pays principle could be implemented such as a tax on CO2 emissions which could have an effect on certain costs of its supply chain.

(16.1.1.8) Primary financial effect of the risk

Select from:

- ☒ Increased indirect [operating] costs

(16.1.1.9) Time horizon over which the risk is anticipated to have a substantive effect on the organization

Select all that apply

- ☒ Medium-term

(16.1.1.10) Likelihood of the risk having an effect within the anticipated time horizons

Select from:

- ☒ More likely than not (50–100%)

(16.1.1.11) Magnitude

Select from:

- ☒ Medium

(16.1.1.12) Are you able to quantify the financial effect of the risk?

Select from:

☒ No

(16.1.1.16) Primary response to risk

Engagement

☒ Engage with suppliers

Climate change

(16.1.1.1) Risk identifier

Select from:

☒ Risk10

(16.1.1.3) Risk type and primary source of the environmental risk

Reputation

☒ Increased stakeholder concern or negative stakeholder feedback

(16.1.1.4) Value chain stage where the risk occurs

Select from:

☒ Direct operations (our own operations)

(16.1.1.5) Country/area where the risk occurs

Select all that apply

☒ France

☒ United States of America

(16.1.1.7) Organization-specific description of risk

Damage to the Company's present or future reputation, among customers and investors as well as to its internal resources in terms of staffing, as a result of not enough significant measures having been taken or a delay in committing to an environmental and social transition, or a failure to comply with transparency requirements which could adversely affect the Company's prospects, results, financial health, borrowing capacity and development.

(16.1.1.8) Primary financial effect of the risk

Select from:

☒ Decreased access to capital

(16.1.1.9) Time horizon over which the risk is anticipated to have a substantive effect on the organization

Select all that apply

☒ Medium-term

(16.1.1.10) Likelihood of the risk having an effect within the anticipated time horizons

Select from:

☒ Unlikely (0–33%)

(16.1.1.11) Magnitude

Select from:

☒ Medium

(16.1.1.12) Are you able to quantify the financial effect of the risk?

Select from:

☒ No

(16.1.1.16) Primary response to risk

Policies and plans

☒ More ambitious environmental commitments and policies

Climate change

(16.1.1.1) Risk identifier

Select from:

☒ Risk11

(16.1.1.3) Risk type and primary source of the environmental risk

Market

☒ Changing customer behavior

(16.1.1.4) Value chain stage where the risk occurs

Select from:

☒ Downstream value chain (distributors or customers)

(16.1.1.5) Country/area where the risk occurs

Select all that apply

- | | |
|---|--|
| <input checked="" type="checkbox"/> Italy | <input checked="" type="checkbox"/> Norway |
| <input checked="" type="checkbox"/> Spain | <input checked="" type="checkbox"/> Sweden |
| <input checked="" type="checkbox"/> Canada | <input checked="" type="checkbox"/> Belgium |
| <input checked="" type="checkbox"/> France | <input checked="" type="checkbox"/> Denmark |
| <input checked="" type="checkbox"/> Greece | <input checked="" type="checkbox"/> Finland |
| <input checked="" type="checkbox"/> Germany | <input checked="" type="checkbox"/> United States of America |
| <input checked="" type="checkbox"/> Ireland | <input checked="" type="checkbox"/> United Kingdom of Great Britain and Northern Ireland |
| <input checked="" type="checkbox"/> Portugal | |
| <input checked="" type="checkbox"/> Netherlands | |
| <input checked="" type="checkbox"/> Switzerland | |

(16.1.1.7) Organization-specific description of risk

A sudden change to the market, especially investor and consumer sentiment regarding environmental issues (use of single-use plastic and rejection of active ingredients), due to scandals in the pharmaceutical industry that could put the Company's reputation or that of its partners at risk, and which could adversely affect the Company's prospects and results, in particular its sales volumes, as well as its financial health and development.

(16.1.1.8) Primary financial effect of the risk

Select from:

☒ Decreased revenues due to reduced demand for products and services

(16.1.1.9) Time horizon over which the risk is anticipated to have a substantive effect on the organization

Select all that apply

☒ Medium-term

☒ Long-term

(16.1.1.10) Likelihood of the risk having an effect within the anticipated time horizons

Select from:

☒ About as likely as not (33–66%)

(16.1.1.11) Magnitude

Select from:

☒ Medium-low

(16.1.1.12) Are you able to quantify the financial effect of the risk?

Select from:

☒ No

(16.1.1.16) Primary response to risk

Policies and plans

☒ Participation in environmental collaborative industry frameworks, initiatives and/or commitments

Climate change

(16.1.1.1) Risk identifier

Select from:

☒ Risk14

(16.1.1.3) Risk type and primary source of the environmental risk

Acute physical (short term, specific events that change the state of nature)

☒ Wildfires

(16.1.1.4) Value chain stage where the risk occurs

Select from:

☒ Direct operations (our own operations)

(16.1.1.5) Country/area where the risk occurs

Select all that apply

☒ France

(16.1.1.7) Organization-specific description of risk

Forest fires can cause disruption to buildings access and local supply chains.

(16.1.1.8) Primary financial effect of the risk

Select from:

☒ Disruption in production capacity

(16.1.1.9) Time horizon over which the risk is anticipated to have a substantive effect on the organization

Select all that apply

- ☒ Short-term
- ☒ Medium-term

(16.1.1.10) Likelihood of the risk having an effect within the anticipated time horizons

Select from:

- ☒ Unlikely (0–33%)

(16.1.1.11) Magnitude

Select from:

- ☒ Low

(16.1.1.12) Are you able to quantify the financial effect of the risk?

Select from:

- ☒ No

(16.1.1.16) Primary response to risk

Infrastructure, technology and spending

- ☒ Increase geographic diversity of facilities

Climate change

(16.1.1.1) Risk identifier

Select from:

- ☒ Risk15

(16.1.1.3) Risk type and primary source of the environmental risk

Chronic physical (gradual changes to the state of nature)

☒ Heat stress

(16.1.1.4) Value chain stage where the risk occurs

Select from:

☒ Downstream value chain (distributors or customers)

(16.1.1.5) Country/area where the risk occurs

Select all that apply

☒ China

☒ India

☒ Israel

☒ United States of America

(16.1.1.7) Organization-specific description of risk

Rising temperatures combined with limited energy resources can lead to an increase in energy demand and associated costs. Pharmaceutical operations are often temperature-controlled activities.

(16.1.1.8) Primary financial effect of the risk

Select from:

☒ Increased production costs

(16.1.1.9) Time horizon over which the risk is anticipated to have a substantive effect on the organization

Select all that apply

☒ Medium-term

(16.1.1.10) Likelihood of the risk having an effect within the anticipated time horizons

Select from:

☒ More likely than not (50–100%)

(16.1.1.11) Magnitude

Select from:

☒ Medium-low

(16.1.1.12) Are you able to quantify the financial effect of the risk?

Select from:

☒ No

(16.1.1.16) Primary response to risk

Policies and plans

☒ Develop a climate transition plan

Climate change

(16.1.1.1) Risk identifier

Select from:

☒ Risk2

(16.1.1.3) Risk type and primary source of the environmental risk

Acute physical (short term, specific events that change the state of nature)

☒ Flooding (coastal, fluvial pluvial, groundwater)

(16.1.1.4) Value chain stage where the risk occurs

Select from:

☒ Direct operations (our own operations)

(16.1.1.5) Country/area where the risk occurs

Select all that apply

☒ France

(16.1.1.7) Organization-specific description of risk

Disruption of R&D and HQ facilities due to heavy rain during Cévenoles episodes.

(16.1.1.8) Primary financial effect of the risk

Select from:

☒ Disruption in production capacity

(16.1.1.9) Time horizon over which the risk is anticipated to have a substantive effect on the organization

Select all that apply

☒ Short-term

☒ Medium-term

(16.1.1.10) Likelihood of the risk having an effect within the anticipated time horizons

Select from:

☒ Likely (66–100%)

(16.1.1.11) Magnitude

Select from:

☒ Medium-low

(16.1.1.12) Are you able to quantify the financial effect of the risk?

Select from:

☒ No

(16.1.1.16) Primary response to risk

Infrastructure, technology and spending

☒ Increase geographic diversity of facilities

(16.1.1.19) Description of response

Risk assessment of premises, maintain drainage system. For our own facilities thorough risk assessment of the premises is conducted to identify areas that are vulnerable to heavy rain and flooding as part of our continuity plan. The company ensures drainage system is well maintained and capable of handling heavy rainfall.
[Add row]

(16.3) Are you aware of any opportunities created by environmental issues which have had a substantive effect on your organization in the reporting year or may in the future?

	Environmental opportunities identified
Climate change	Select from: <input checked="" type="checkbox"/> Yes, we have identified opportunities, and some/all are being realized

[Fixed row]

(16.3.1) Provide details of the opportunities created by environmental issues which have had a substantive effect on your organization in the reporting year or may in the future.

Climate change

(16.3.1.1) Opportunity identifier

Select from:

☒ Opp2

(16.3.1.3) Opportunity type and primary source

Energy source

☒ Use of renewable energy sources

(16.3.1.4) Value chain stage where the opportunity occurs

Select from:

☒ Direct operations (our own operations)

(16.3.1.5) Country/area where the opportunity occurs

Select all that apply

☒ France

(16.3.1.7) Organization specific description

Premises located in France consumed the national french energy mix, which due to some nuclear plant maintenance had a lower ratio of renouvelable energy this year, thus a bigger carbone impact. At the end of the reportinh year, we were able to upgrade our electricity supply contract to a 100 % renewable energy mix during the contrat renegotiation in order to reduce our carbon footprint.

(16.3.1.8) Primary financial effect of the opportunity

Select from:

☒ Other, please specify :Increased in direct operation costs but decrease in carbone scope II

(16.3.1.9) Time horizon over which the opportunity is anticipated to have a substantive effect on the organization

Select all that apply

☒ Short-term

(16.3.1.10) Likelihood of the opportunity having an effect within the anticipated time horizon

Select from:

☒ Likely (66–100%)

(16.3.1.11) Magnitude

Select from:

☒ Medium-low

[Add row]

C17. SME Governance

(17.1) Is there responsibility for environmental issues within your organization?

	Responsibility for this environmental issue
Climate change	Select from: <input checked="" type="checkbox"/> Yes

[Fixed row]

(17.1.1) Provide the highest positions or committees with responsibility for environmental issues (do not include the names of individuals).

Climate change

(17.1.1.1) Position of individual or committee with responsibility

Committee

☒ Environmental, Social, Governance committee

(17.1.1.2) Environmental responsibilities of this position

Risks and opportunities

- ☒ Assessing future trends in environmental risks and opportunities
- ☒ Assessing environmental risks and opportunities
- ☒ Managing environmental risks and opportunities

Policies, commitments, and targets

- ☒ Setting corporate environmental policies and/or commitments
- ☒ Monitoring compliance with corporate environmental policies and/or commitments
- ☒ Setting corporate environmental targets
- ☒ Measuring progress towards environmental corporate targets

Engagement

- ☒ Managing public policy engagement related to environmental issues
- ☒ Managing value chain engagement related to environmental issues

Strategy and financial planning

- ☒ Developing a climate transition plan
- ☒ Developing a business strategy which considers environmental issues
- ☒ Managing priorities related to innovation/low-environmental impact products or services (including R&D)
- ☒ Managing environmental reporting, audit, and verification processes

Other

- ☒ Providing employee incentives related to environmental performance

(17.1.1.3) Who in the organization does this position report to

Select from:

- ☒ Reports to the board directly

(17.1.1.4) Frequency of reporting on environmental issues via this reporting line

Select from:

- ☒ As important matters arise

(17.1.1.5) Please explain

Climate-related issues are integrated as part of our Corporate Social Responsibility, environmental impact of our operations and products. As such the ESG Committee role and missions are: - to examine the Company's extra-financial matters and to provide advice and recommendations to the Supervisory Board, - to

evaluate the Company's ESG policy and the related results, - to measure the progress and achievement of the ESG objectives and to propose any relevant changes to those objectives, - to review the Company's ESG strategy and provide advice and recommendations to the Supervisory Board, - to approve the Company's ESG report. The ESG meeting meets quarterly and when an important matter arises As our company will strengthen its ESG management, the ESG committee and ESG pilote team will also: - Establish science-based traget and measure progress toward them, - Conduct several environmental scenario plan, - Implement the developped climate transition plan, - Expand its level of control on the value chain Medincell implemented an ESG bonus based on the ESG road map accomplishment as an incentives to all employee. The CSR bonus rewards specific efforts on a CSR thematic, in the form of an increase in the Company bonus linked to strategy development objectives. For the 2023 fiscal year, this increase amounts to 10 % of the collective bonus, obtained in half and representing an additional €8,000 to be distributed among employees

[Add row]

(17.2) Does your organization have an environmental policy that addresses environmental issues?

	Does your organization have any environmental policies?
	Select from: <input checked="" type="checkbox"/> Yes

[Fixed row]

(17.2.1) Provide details of your environmental policies.

Row 1

(17.2.1.1) Environmental issues covered

Select all that apply
☒ Climate change

(17.2.1.2) Level of coverage

Select from:

- ☒ Organization-wide

(17.2.1.3) Value chain stages covered

Select all that apply

- ☒ Direct operations (our own organization)
- ☒ Upstream activities (suppliers)
- ☒ Downstream activities (distributors or customers)

(17.2.1.4) Explain the coverage

With global health challenges at heart and as part of its commitment to minimize its environmental impact, MedinCell is committed to integrating climate action and sustainability into the lifecycle of its products and to preserving biodiversity and resources for future generations. Our environmental policy describes MedinCell's commitments to comply with the applicable legislation and the current objectives to minimize its impact on the environment. It sets ambitious climate related goals to be in line with Paris Agreements and United Nations Sustainable Development Goals and places environmental management at the heart of all our activities. As described in our CSR Policy, MedinCell commits to:

- Develop products with a reduced environmental impact and strive to design new sustainable technologies,*
- Strive to reduce manufacturing processes waste and emissions and aim to have a lean process starting with Quality by Design for technology transfer to our partners,*
- Minimize our global footprint by reducing and sorting waste, rationalizing energy use and reducing emissions. As described in our Code of Ethic and supplier Code, we expect our suppliers and business partners to operate their business in an environmentally responsible manner. We believe that enrolling partners that are committed to more sustainable practices fosters and accelerates continuous improvement and keeps us in line with our ambition to develop low environmental impact products*

(17.2.1.5) Environmental policy content

Environmental commitments

- ☒ Commitment to comply with regulations and mandatory standards
- ☒ Commitment to stakeholder engagement and capacity building on environmental issues
- ☒ Other environmental commitment, please specify :Develop products with a reduced environmental impact and strive to design new sustainable technologies

Climate-specific commitments

- ☒ Other climate-related commitment, please specify :To be in line with the Paris Agreements aiming at limiting global warming, MedinCell strives to reduce its carbon emissions as much as possible. We assess our carbon footprint as precisely as possible regarding the scopes 1, 2 and 3 of the GreenHouse

Social commitments

- ☒ Commitment to respect internationally recognized human rights
- ☒ Other social commitment, please specify :Right to Health, others social commitment are part of our Codes of Ethics and Conduct, and Supplier Code

Additional references/Descriptions

- ☒ Description of environmental requirements for procurement
- ☒ Description of grievance/whistleblower mechanism to monitor non-compliance with the environmental policy and raise/address/escalate any other greenwashing concerns
- ☒ Other, additional references/descriptions please specify :Reference to the whistleblower mechanism are part of our Codes of Ethics and Conduct, and Supplier Code, ou annaul ESG repport reference timebound environmental achievement and targets.

Row 2

(17.2.1.2) Level of coverage

Select from:

- ☒ Organization-wide

(17.2.1.3) Value chain stages covered

Select all that apply

- ☒ Direct operations (our own organization)
- ☒ Upstream activities (suppliers)
- ☒ Downstream activities (distributors or customers)

(17.2.1.4) Explain the coverage

As a committed player for Global Health, we advocate that access to clean water is essential and a basic human right. We strive to protect the water resources by reducing our direct or indirect impact on water. We aim at reducing our water consumption, treating properly any eluent, and reducing or eliminating direct or indirect water pollution. We follow our water consumption to detect early on any leak or usage deviance. In our facilities, water that is in contact with chemicals or solvents is never linked to the city water network and is discarded in specific containers to be properly treated. Any leak of chemicals in the environment is prevented by an impervious floor in the laboratory, as well as retention containers in the hazardous waste storage area and any chemicals storage. Actions and procedures are in place to react to any leak, spillage in the shortest possible time. We assess our water consumption to determine the most water consuming steps in the process, and

to take actions to reduce future manufacturing consumption. Our technology allows for some product to reduce the necessary amount of drug needed for a treatment thus reducing the initial drug manufacturing need and water contamination through human medicine excretions.

(17.2.1.5) Environmental policy content

Environmental commitments

- ☒ Commitment to comply with regulations and mandatory standards
- ☒ Commitment to stakeholder engagement and capacity building on environmental issues
- ☒ Other environmental commitment, please specify :Develop technologies that allows for some product to reduce the necessary amount of drug needed for a treatment thus reducing the initial drug manufacturing need and water contamination through human medicine excretions

[Add row]

C18. SME Business Strategy

(18.1) Have risks and opportunities created by environmental issues influenced your strategy and/or financial planning?

(18.1.1) Environmental risks and/or opportunities have affected your strategy and/or financial planning

Select from:

☒ Yes, both strategy and financial planning

[Fixed row]

(18.1.1) Describe where and how risks and opportunities created by environmental issues have influenced your strategy and/or financial planning?

Strategy

(18.1.1.1) Business areas that have been affected

Select all that apply

☒ Products and services

(18.1.1.3) Effect type

Select all that apply

☒ Risks

(18.1.1.5) Describe how environmental risks and/or opportunities have affected your strategy and/or financial planning in this area

Active pharmaceutical ingredient in water is a concern. A more efficient use of API through technology (bioavailability and patient compliance (Drug regimens are only followed on average at 50 % for a oral product)), and a potentially leaner production (less water intensive) could lead to a greater value of our product(s)..

Financial planning

(18.1.1.2) Financial planning elements that have been affected

Select all that apply

- ☒ Direct costs
- ☒ Indirect costs

(18.1.1.3) Effect type

Select all that apply

- ☒ Risks
- ☒ Opportunities

(18.1.1.4) Environmental issues relevant to the risks and/or opportunities that have affected your strategy and/or financial planning in this area

Select all that apply

- ☒ Climate change

(18.1.1.5) Describe how environmental risks and/or opportunities have affected your strategy and/or financial planning in this area

Premises located in France consumed the national french energy mix, which due to some nuclear plant maintenance had a lower ratio of renewable energy this year, thus a bigger carbone impact. At the end of the reporting year, we were able to upgrade our supply contract to a 100 % renewable energy mix during the contrat renegotiation in order to reduce our carbon footprint.

Strategy

(18.1.1.1) Business areas that have been affected

Select all that apply

- ☒ Upstream/downstream value chain

(18.1.1.3) Effect type

Select all that apply

☒ Risks

(18.1.1.4) Environmental issues relevant to the risks and/or opportunities that have affected your strategy and/or financial planning in this area

Select all that apply

☒ Climate change

(18.1.1.5) Describe how environmental risks and/or opportunities have affected your strategy and/or financial planning in this area

Evaluation in progress, value chain impact on environment as a whole will be tackle other the next coming years.

Strategy

(18.1.1.1) Business areas that have been affected

Select all that apply

☒ Investment in R&D

(18.1.1.3) Effect type

Select all that apply

☒ Risks

☒ Opportunities

(18.1.1.4) Environmental issues relevant to the risks and/or opportunities that have affected your strategy and/or financial planning in this area

Select all that apply

☒ Climate change

(18.1.1.5) Describe how environmental risks and/or opportunities have affected your strategy and/or financial planning in this area

This year our R&D department has appointed 17% of its researchers to the development of technology that could limit drugs 'environmental impact.

Strategy

(18.1.1.1) Business areas that have been affected

Select all that apply

☒ Operations

(18.1.1.3) Effect type

Select all that apply

☒ Opportunities

(18.1.1.4) Environmental issues relevant to the risks and/or opportunities that have affected your strategy and/or financial planning in this area

Select all that apply

☒ Climate change

(18.1.1.5) Describe how environmental risks and/or opportunities have affected your strategy and/or financial planning in this area

Our company has invested in an electric vehicle since 2019 - Our company has developed a commuting plan for its employees including carpooling application. - Our company has equipped its new building with central thermic control, and detection LED lightning. - This year our company as implemented a €50 Sustainable Mobility Package to help employee. Among other things, this financial allowance enables the purchase of equipment for the first and last kilometers to reach the public transport network, bike maintenance and the renewal of safety accessories.

Strategy

(18.1.1.1) Business areas that have been affected

Select all that apply

☒ Operations

(18.1.1.3) Effect type

Select all that apply

☒ Risks

(18.1.1.4) Environmental issues relevant to the risks and/or opportunities that have affected your strategy and/or financial planning in this area

Select all that apply

☒ Climate change

(18.1.1.5) Describe how environmental risks and/or opportunities have affected your strategy and/or financial planning in this area

Material Investments are assessed through their total cost of ownership, which includes energy and water consumption, maintenance cost...

[Add row]

(18.2) Does your organization's strategy include a climate transition plan?

	Transition plan
	Select from: <input checked="" type="checkbox"/> No, but we are developing a climate transition plan within two years

[Fixed row]

(18.3) Do you engage with suppliers, customers, and other stakeholders within your value chain on environmental issues?

Suppliers

(18.3.1) Engaging with this stakeholder on environmental issues

Select from:

☒ Yes

(18.3.2) Environmental issues covered

Select all that apply

☒ Climate change

☒ Water

(18.3.4) Type of engagement

Select all that apply

☒ Capacity building

☒ Information collection

(18.3.5) Details of engagement

Engagement paper audit and Data sharing for scope 3 calculation and improvement..

Customers

(18.3.1) Engaging with this stakeholder on environmental issues

Select from:

☒ Yes

(18.3.2) Environmental issues covered

Select all that apply

☒ Water

(18.3.4) Type of engagement

Select all that apply

- ☒ Innovation and collaboration
- ☒ Education/ Information sharing

(18.3.5) Details of engagement

Commercial partner information sharing about our technology potential of reduction of water contamination. Community (general population) awareness raising about medicine compliance and proper disposal of them. We are engaging discussions with our main partners to be able to access our commun product life cycle impact as soon as possible.

Investors and shareholders

(18.3.1) Engaging with this stakeholder on environmental issues

Select from:

- ☒ Yes

(18.3.2) Environmental issues covered

Select all that apply

- ☒ Climate change
- ☒ Forests
- ☒ Water

(18.3.4) Type of engagement

Select all that apply

- ☒ Information collection
- ☒ Education/ Information sharing

(18.3.5) Details of engagement

Climate and environmental risk and opportunity reporting. Road map, carbon footprint and goals sharing. General performance disclosure.

Other value chain stakeholders, please specify

(18.3.1) Engaging with this stakeholder on environmental issues

Select from:

☒ Yes

(18.3.2) Environmental issues covered

Select all that apply

☒ Climate change

(18.3.4) Type of engagement

Select all that apply

☒ Capacity building

☒ Financial incentives

☒ Information collection

☒ Innovation and collaboration

☒ Education/ Information sharing

(18.3.5) Details of engagement

Local community capacity building (Commuting to and from work accounts for a significant proportion of the Company's greenhouse gas emissions. In the middle of 2021, we have committed ourselves, in consultation with local players and the Montpellier Metropolis, to developing a mobility plan for the years 2022-2025. An annual employee mobility survey enables us to estimate the number of journeys made and the associated emissions. These estimates have a high degree of uncertainty but allow us to monitor the relative contribution of the various sources of emissions. In particular, Medincell was one of the first 30 companies to rally behind the Montpellier Metropole's car-sharing initiative, rolling out the Klaxit car-sharing app at the end of 2021. After this highly encouraging trial phase, the Metropole extended the scheme to the general public in January 2022. We also encourage our employees to make the transition to more sustainable mobility by providing them with five electric car charging stations as well as a parking at covered bicycles (equivalent to 4 car spaces). Regular communications allow our employees to be informed about the financial aid available for the acquisition of an electric bike or the maintenance of mechanical bikes. In synergy with the introduction in December 2023 of free public transport every day for all residents of the Metropole, we have introduced a 50-euro Sustainable Mobility Package. Among other things, this financial allowance enables the purchase of equipment for the first and last kilometers to reach the public transport network, bike maintenance and the renewal of safety accessories.). Employee awareness raising, commute plan, financial incentives.

[Fixed row]

C19. SME Environmental Performance – Consolidation Approach

(19.1) Select the consolidation approach used by your organization to determine the climate-related impacts that are reported on throughout your response. Note that this option should align with your chosen approach for consolidating your GHG inventory.

(19.1.1) Consolidation approach used

Select from:

☒ Financial control

(19.1.2) Provide the rationale for the choice of consolidation approach

Although our Group's structure is quite simple, this approach aligns with our financial reporting, as it considers the financial control the organization has over its operations and ensures consistency with financial reporting. It allows us to provide a more comprehensive view of the organization, and ensures that the organization remains compliant with relevant regulations and standards. This also makes it easier to integrate GHG reporting with financial statements and other financial disclosures. By accounting for all emissions from operations under financial control, it will be easier for the organization to manage and mitigate risks associated with climate-related impacts.

[Fixed row]

C20. SME Environmental Performance – Climate Change

(20.1) Do you evaluate your organization's greenhouse gas (GHG) emissions? Note that you can measure your emissions or estimate them using the assistance of a carbon accounting tool.

Scope 1 (direct emissions from owned or controlled activities)

(20.1.1) Emissions evaluated

Select from:

☒ Yes, we use tailored in-house or paid-for resources to calculate them

(20.1.4) Indicate whether you had any major barriers or challenges evaluating your emissions in the reporting year

Select from:

☒ Yes

(20.1.5) Please explain the major barriers or challenges in evaluating your emissions

less suppliers have communicated on their footprint due to the regress of the CSRD and "fear" of green bashing. it was possible to match only 21 % (compared to 28 % last year) of the purchasing volume to a supplier's carbon emissions ratio (scope 3)

(20.1.6) Main measures which have helped, or would help, to manage or resolve the challenges

Select all that apply

☒ Other, please specify :enforced legislation

(20.1.8) Indicate if you are providing emissions data for past reporting years

Select from:

☒ Yes

(20.1.9) Number of past reporting years you will be providing emissions data for

Select from:

☒ 5 years

Scope 2 (indirect emissions from purchased electricity, heat, steam or cooling)

(20.1.1) Emissions evaluated

Select from:

☒ Yes, we use tailored in-house or paid-for resources to calculate them

(20.1.2) Scope 2 approach

Select from:

☒ We are reporting a Scope 2 market-based figure

(20.1.4) Indicate whether you had any major barriers or challenges evaluating your emissions in the reporting year

Select from:

☒ No

(20.1.8) Indicate if you are providing emissions data for past reporting years

Select from:

☒ Yes

(20.1.9) Number of past reporting years you will be providing emissions data for

Select from:

☒ 5 years

Scope 3 (indirect emissions in upstream/downstream value chain)

(20.1.1) Emissions evaluated

Select from:

☒ Yes, we use tailored in-house or paid-for resources to calculate them

(20.1.4) Indicate whether you had any major barriers or challenges evaluating your emissions in the reporting year

Select from:

☒ No

(20.1.8) Indicate if you are providing emissions data for past reporting years

Select from:

☒ Yes

(20.1.9) Number of past reporting years you will be providing emissions data for

Select from:

☒ 5 years

[Fixed row]

(20.2) Select the name of the standard, protocol, or methodology you have used to collect activity data and calculate emissions.

Select all that apply

☒ Bilan Carbone, ABC

(20.3) Are there any sources (e.g. facilities, specific GHGs, activities, geographies, etc.) of Scope 1, Scope 2 or Scope 3 emissions which are attributed to the entities you are including in your CDP response which are not included in your disclosure?

Select from:

☒ No

(20.4) What were your organization's gross global Scope 1 emissions in metric tons CO₂e?

Reporting year

(20.4.1) Gross global Scope 1 emissions (metric tons CO2e)

0.98

(20.4.3) Methodological details

The Company uses electricity as its sole energy source, and does not rely on the combustion of fossil fuels or biomass for its energy supply. In the 2024-2025 financial year, a leak was detected and repaired on a valve in a small air-conditioning system. This leak led to the fugitive emission of R-32 refrigerant gas equivalent to 0.979 t CO2e.

Past year 1

(20.4.1) Gross global Scope 1 emissions (metric tons CO2e)

0.78

Past year 2

(20.4.1) Gross global Scope 1 emissions (metric tons CO2e)

0

Past year 3

(20.4.1) Gross global Scope 1 emissions (metric tons CO2e)

0

Past year 4

(20.4.1) Gross global Scope 1 emissions (metric tons CO2e)

0

Past year 5

(20.4.1) Gross global Scope 1 emissions (metric tons CO2e)

0

[Fixed row]

(20.5) What were your organization's gross global Scope 2 emissions in metric tons CO2e?

Reporting year

(20.5.2) Gross global Scope 2, market-based emissions (metric tons CO2e)

11.27

(20.5.5) Methodological details

Indirect emissions associated with energy are solely those linked to the consumption of electricity from our French energy provider with a renewable energy sources contract. Part of the electricity consumed is for electric vehicles (Company and staff) and for IT equipment. The scope 2 market-based carbon footprint is therefore 11.27 t CO2e (GRI 305-2) and the scope 2 location-based carbon footprint is therefore 15.43 t CO2e (GRI 305-2).

Past year 1

(20.5.2) Gross global Scope 2, market-based emissions (metric tons CO2e)

40.82

(20.5.5) Methodological details

The year increase is due to a small increase of consumption, and to a big increase of the french mix available that year to our provider (less nuclear in the mix). It was decided to switch contract to a 100% renewable contract to lessen our footprint.

Past year 2

(20.5.2) Gross global Scope 2, market-based emissions (metric tons CO2e)

12.86

Past year 3

(20.5.2) Gross global Scope 2, market-based emissions (metric tons CO2e)

9.06

Past year 4

(20.5.2) Gross global Scope 2, market-based emissions (metric tons CO2e)

7.64

Past year 5

(20.5.2) Gross global Scope 2, market-based emissions (metric tons CO2e)

7.05
[Fixed row]

(20.7) Account for your organization’s gross global Scope 3 emissions, disclosing and explaining any exclusions.

Purchased goods and services

(20.7.1) Evaluation status

Select from:
☒ Relevant, calculated

(20.7.2) Emissions in reporting year (metric tons CO2e)

1884

Capital goods

(20.7.1) Evaluation status

Select from:

☒ Relevant, calculated

(20.7.2) Emissions in reporting year (metric tons CO2e)

276

Fuel-and-energy-related activities (not included in Scope 1 or 2)

(20.7.1) Evaluation status

Select from:

☒ Not relevant, explanation provided

(20.7.3) Please explain

Consumption of electricity only including company owned vehicle.

Upstream transportation and distribution

(20.7.1) Evaluation status

Select from:

☒ Not relevant, explanation provided

(20.7.3) Please explain

As R&D entity, we don't have a regular flow of raw material incoming. Upstream transportation is mainly the delivery of purchased goods for which the transport is accounted for in the bills and accounted in the purchased and goods and services category.

Waste generated in operations

(20.7.1) Evaluation status

Select from:

☒ Relevant, calculated

(20.7.2) Emissions in reporting year (metric tons CO2e)

10

Business travel

(20.7.1) Evaluation status

Select from:

☒ Relevant, calculated

(20.7.2) Emissions in reporting year (metric tons CO2e)

554

Employee commuting

(20.7.1) Evaluation status

Select from:

☒ Relevant, calculated

(20.7.2) Emissions in reporting year (metric tons CO2e)

142

Upstream leased assets

(20.7.1) Evaluation status

Select from:

☒ Relevant, calculated

(20.7.2) Emissions in reporting year (metric tons CO2e)

43

Downstream transportation and distribution

(20.7.1) Evaluation status

Select from:

☒ Not evaluated

(20.7.3) Please explain

As an R&D entity we don't have a regular flow of product our facilities. Our first product on the market is commercialised through a business partner (Big pharma), which does not keep track of its GHG emission at product level.

Processing of sold products

(20.7.1) Evaluation status

Select from:

☒ Relevant, not yet calculated

(20.7.3) Please explain

The product sold with our technology is commercialised through a big pharmaceutical company and delivered in a clinical setting to the patients. Our business partner doesn't have data on the different processings of the product by health practitioners and health institution. Processing of the product may involve temperature controlled storage.

Use of sold products

(20.7.1) Evaluation status

Select from:

☒ Not relevant, explanation provided

(20.7.3) Please explain

The product sold with our technology is commercialised through a big pharmaceutical company and delivered in a clinical setting to the patients. Our business partner doesn't have data on the different processings of the product by health practitioners and health institution. But our product is directly injectable under the patient skin and doesn't required any external energy use.

End of life treatment of sold products

(20.7.1) Evaluation status

Select from:

☒ Relevant, not yet calculated

(20.7.3) Please explain

The product sold with our technology is commercialised through a big pharmaceutical company and delivered in a clinical setting to the patients. Our business partner doesn't have data on the different processings of the product by health practitioners and health institution. Our product is an biodegradable injectable medicine, but its secondary and primary packagings recycling & treatment are to be taken into account notably the treatment of syringes.

Downstream leased assets

(20.7.1) Evaluation status

Select from:

☒ Not relevant, explanation provided

(20.7.3) Please explain

No downstream assets

Franchises

(20.7.1) Evaluation status

Select from:

☒ Not relevant, explanation provided

(20.7.3) Please explain

No franchises

Investments

(20.7.1) Evaluation status

Select from:

☒ Not relevant, explanation provided

(20.7.3) Please explain

Not our business, very few money placements

Other (upstream)

(20.7.1) Evaluation status

Select from:

☒ Relevant, not yet calculated

(20.7.3) Please explain

IT carbon footprint, notably externalised is to be taken into account although direct energy use and our own server and some software (through licenses) are already accounted for in scope 2 and in scope 3 under goods and services.

Other (downstream)

(20.7.1) Evaluation status

Select from:

☒ Not relevant, explanation provided

(20.7.3) Please explain

no other downstream posts
[Fixed row]

(20.7.1) Disclose or restate your Scope 3 emissions data for previous years.

Past year 1

(20.7.1.1) End date

03/30/2024

(20.7.1.2) Scope 3: Purchased goods and services (metric tons CO2e)

3169

(20.7.1.3) Scope 3: Capital goods (metric tons CO2e)

431

(20.7.1.6) Scope 3: Waste generated in operations (metric tons CO2e)

10

(20.7.1.7) Scope 3: Business travel (metric tons CO2e)

213

(20.7.1.8) Scope 3: Employee commuting (metric tons CO2e)

137

(20.7.1.9) Scope 3: Upstream leased assets (metric tons CO2e)

41

Past year 2

(20.7.1.1) End date

03/30/2023

(20.7.1.2) Scope 3: Purchased goods and services (metric tons CO2e)

5120

(20.7.1.3) Scope 3: Capital goods (metric tons CO2e)

482

(20.7.1.6) Scope 3: Waste generated in operations (metric tons CO2e)

9

(20.7.1.7) Scope 3: Business travel (metric tons CO2e)

248

(20.7.1.8) Scope 3: Employee commuting (metric tons CO2e)

138

(20.7.1.9) Scope 3: Upstream leased assets (metric tons CO2e)

255

Past year 3

(20.7.1.1) End date

03/30/2022

(20.7.1.3) Scope 3: Capital goods (metric tons CO2e)

536

(20.7.1.6) Scope 3: Waste generated in operations (metric tons CO2e)

10

(20.7.1.7) Scope 3: Business travel (metric tons CO2e)

43

(20.7.1.8) Scope 3: Employee commuting (metric tons CO2e)

92

(20.7.1.19) Comment

limited data and year impacted by the covid pandemia

Past year 4

(20.7.1.1) End date

03/30/2021

(20.7.1.6) Scope 3: Waste generated in operations (metric tons CO2e)

6

(20.7.1.7) Scope 3: Business travel (metric tons CO2e)

3

(20.7.1.19) Comment

limited data and year impacted by the covid pandemia

Past year 5

(20.7.1.1) End date

03/30/2020

(20.7.1.7) Scope 3: Business travel (metric tons CO2e)

19

(20.7.1.19) Comment

limited data

[Fixed row]

(20.8) Indicate the verification/assurance status that applies to your reported emissions.

	Verification/assurance status
Scope 1 (direct emissions from owned or controlled activities)	Select from: <input checked="" type="checkbox"/> No third-party verification or assurance
Scope 2 (location-based or market-based indirect emissions from purchased electricity, heat, steam or cooling)	Select from: <input checked="" type="checkbox"/> No third-party verification or assurance
Scope 3 (indirect emissions in upstream/downstream value chain)	Select from: <input checked="" type="checkbox"/> No third-party verification or assurance

[Fixed row]

(20.9) How do your gross global emissions (Scope 1 and 2 combined) for the reporting year compare to those of the previous reporting year?

(20.9.1) How do your gross global emissions (Scope 1 and 2 combined) for the reporting year compare to those of the previous reporting year?

Select from:

☒ Decreased

(20.9.2) Reason

Select all that apply

☒ Change in renewable energy consumption

(20.9.3) Please explain

On an equivalent installation basis and with consumption up 4.9 %, the scope 2 carbon emission has decreased through the evolution of our electricity supply contract to a 100 % renewable energy mix.

[Fixed row]

(20.10) Break down your total gross global Scope 1 emissions by business activity.

	Activity	Scope 1 emissions (metric tons CO2e)
Row 1	Facilities refrigerant system	0.98

[Add row]

(20.11) Break down your total gross global Scope 2 emissions by business activity.

	Activity	Scope 2, location-based (metric tons CO2e)	Scope 2, market-based (metric tons CO2e)
Row 1	Offices (including external premises, staff's personal vehicle)	5.7	4.1
Row 2	Laboratory and technical annexes	9.7	7.2
Row 3	Company's electric vehicle	0.01	0.01

[Add row]

(20.15) Does your organization break down its electricity consumption by country/area.

Select from:

☒ Yes

(20.15.1) Provide a breakdown by country/area of your purchased or acquired electricity consumption in MWh.

Row 1

(20.15.1.1) Country/area

Select from:

☒ France

(20.15.1.2) MWh from renewable sources

573469

(20.15.1.3) MWh from non-renewable sources

150882

(20.15.1.4) Total (renewable + non-renewable) MWh

724351.00

(20.15.1.5) Comment

change of contract during the year to have 100% a renewable energy mix.

[Add row]

(20.16) Did you have an emissions or other climate-related target that was active in the reporting year?

(20.16.1) Emissions or other climate-related target

Select all that apply

- ☒ Emissions intensity target
- ☒ Target to increase or maintain low-carbon energy consumption or production
- ☒ Other climate-related target

[Fixed row]

(20.16.2) Provide details of your emissions intensity targets and progress made against those targets.

Row 1

(20.16.2.1) Target reference number

Select from:

- ☒ Int1

(20.16.2.2) Date target was set

03/30/2023

(20.16.2.3) Target coverage

Select from:

☒ Business activity

(20.16.2.4) Scopes covered by target

Select all that apply

☒ Scope 2 (indirect emissions from purchased electricity, heat, steam or cooling)

(20.16.2.5) Scope 2 accounting method

Select from:

☒ Market-based

(20.16.2.7) Intensity metric

Select from:

☒ Metric tons CO₂e per square meter

(20.16.2.8) End date of base year

03/30/2019

(20.16.2.9) Intensity figure in base year for all selected Scopes

178.2

(20.16.2.10) End date of target

03/30/2031

(20.16.2.11) Targeted reduction from base year (%)

12.45

(20.16.2.12) Intensity figure at end date of target for all selected Scopes

(20.16.2.13) Intensity figure in reporting year for all selected Scopes

126

(20.16.2.14) % of target achieved relative to base year

235.28

(20.16.2.15) Target status in reporting year*Select from:*☒ Achieved**(20.16.2.16) Is this a science-based target?***Select from:*☒ No, but we anticipate setting one in the next two years**(20.16.2.18) Explain target coverage and identify any exclusions**

By 2030, we aim to stabilize the energy intensity of our offices (coworking or meeting spaces excluding server installations) at 40 kWh/m2/year for the HVAC component and 116 kWh/m2/year for the USE component. Office buildings: achieve the reduction target set by France ("tertiary regulations").

*[Add row]***(20.16.3) Provide details of any other climate-related targets that were active in the reporting year.****Row 1****(20.16.3.1) Active climate-related target***Select from:*☒ Target to increase or maintain low-carbon energy consumption or production

(20.16.3.2) Target reference number

Select from:

☒ Oth1

(20.16.3.3) Date target was set

03/30/2023

(20.16.3.4) Target coverage

Select from:

☒ Business activity

(20.16.3.6) End date of base year

09/24/2024

(20.16.3.7) End date of target

03/30/2030

(20.16.3.8) Description of target

Laboratory: improve and maintain energy intensity in line with the Paris Agreement target. Quantitative target under evaluation because of Laboratory's extension.

(20.16.3.9) Target status in reporting year

Select from:

☒ New

(20.16.3.10) Is this target part of an overarching initiative?

Select all that apply

☒ No, it's not part of an overarching initiative

(20.16.3.11) Explain target coverage and identify any exclusions

By 2030 We would also like to stabilize the energy intensity of our laboratory in relation to the number of FTE R&D staff at a target value defined at after the laboratory's construction work and two reference years.

[Add row]

(20.17) Did you have emissions reduction initiatives that were active within the reporting year? Note that this can include those in the planning and/or implementation phases.

	Emissions reduction initiative
	Select from: <input checked="" type="checkbox"/> Yes

[Fixed row]

(20.17.1) Provide details on the emissions reduction initiatives implemented in the reporting year in the table below.

Row 1

(20.17.1.1) Initiative type

Low-carbon energy consumption

☒ Low-carbon electricity mix

(20.17.1.2) Scope(s) or Scope 3 category(ies) where emissions savings occur

Select all that apply

☒ Scope 2 (market-based)

(20.17.1.3) Voluntary/ Mandatory

Select from:

☒ Voluntary

(20.17.1.4) Are you able to estimate CO2e savings and financial impacts?

Select from:

☒ Yes

(20.17.1.5) Estimated annual CO2e savings (metric tons CO2e)

31

(20.17.1.6) Investment required (unit currency – as specified in 14.2)

2896

(20.17.1.7) Annual monetary savings (unit currency – as specified in 14.2)

0

(20.17.1.8) Payback period

Select from:

☒ No payback

(20.17.1.9) Estimated lifetime of the initiative

Select from:

☒ 3-5 years

[Add row]

C21. SME Sign Off

(21.1) Is any environmental information included in your CDP response (not already reported in 20.8) is verified and/or assured by a third party?

Select from:

☒ No, but we plan to obtain third-party verification/assurance of other environmental information in our CDP response within the next two years

(21.2) Provide the following information for the person that has signed off (approved) your CDP response.

(21.2.1) Job title

ESG senior manager

(21.2.2) Corresponding job category

Select from:

☒ Environment/Sustainability manager

[Fixed row]

